These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17555471)

  • 21. Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion.
    Hao S; Lin P; Medeiros LJ; Fang L; Carballo-Zarate AA; Konoplev SN; Sargent RL; Weber DM; Thomas SK; Manasanch EE; Orlowski RZ; Lu X
    Mod Pathol; 2017 Oct; 30(10):1378-1386. PubMed ID: 28664940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases.
    Deng S; Xu Y; An G; Sui W; Zou D; Zhao Y; Qi J; Li F; Hao M; Qiu L
    Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):286-91. PubMed ID: 25640025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A possible role of the P53 gene deletion as a prognostic factor in multiple myeloma.
    Ortega MM; Melo MB; De Souza CA; Lorand-Metze I; Costa FF; Lima CS
    Ann Hematol; 2003 Jul; 82(7):405-9. PubMed ID: 12783209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.
    Thakurta A; Ortiz M; Blecua P; Towfic F; Corre J; Serbina NV; Flynt E; Yu Z; Yang Z; Palumbo A; Dimopoulos MA; Gutierrez NC; Goldschmidt H; Sonneveld P; Avet-Loiseau H
    Blood; 2019 Mar; 133(11):1217-1221. PubMed ID: 30692124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions.
    Chang H; Sloan S; Li D; Keith Stewart A
    Br J Haematol; 2004 Nov; 127(3):280-4. PubMed ID: 15491286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
    An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma.
    Chang H; Ning Y; Qi X; Yeung J; Xu W
    Br J Haematol; 2007 Oct; 139(1):51-4. PubMed ID: 17854306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.
    Gaballa S; Saliba RM; Srour S; Lu G; Brammer JE; Shah N; Bashir Q; Patel K; Bock F; Parmar S; Hosing C; Popat U; Delgado R; Rondon G; Shah JJ; Manasanch EE; Orlowski RZ; Champlin R; Qazilbash MH
    Am J Hematol; 2016 Oct; 91(10):E442-7. PubMed ID: 27420405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Investigation of the molecular changes in patients with multiple myeloma by fluorescence in situ hybridization].
    Yang RF; Li CM; Chen LJ; Qiu HR; Yang H; Liu P; Xu JR; Li JY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Oct; 27(5):567-70. PubMed ID: 20931539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.
    Chang H; Jiang N; Jiang H; Saha MN; Qi C; Xu W; Reece D
    Haematologica; 2010 Sep; 95(9):1542-7. PubMed ID: 20421271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
    Hao S; Lu X; Gong Z; Bassett RL; Hu S; Konoplev SN; Tang G; Li S; Xu J; Khanlari M; Lee HC; Manasanch EE; Weber DM; Orlowski RZ; Medeiros LJ; Lin P
    Mod Pathol; 2021 Feb; 34(2):327-335. PubMed ID: 32908255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen.
    Kelley TW; Baz R; Hussein M; Karafa M; Cook JR
    Hum Pathol; 2009 Mar; 40(3):405-12. PubMed ID: 19070887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma.
    Stokke T; Galteland E; Holte H; Smedshammer L; Suo Z; Smeland EB; Børresen-Dale AL; DeAngelis P; Steen HB
    Int J Cancer; 2000 Jul; 89(4):313-24. PubMed ID: 10956404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allelic loss at TP53 is not related to p53 protein overexpression in primary human endometrial carcinomas.
    Semczuk A; Marzec B; Skomra D; Roessner A; Cybulski M; Rechberger T; Schneider-Stock R
    Oncology; 2005; 69(4):317-25. PubMed ID: 16293976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
    Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
    Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.
    Jeon YK; Park K; Park CK; Paek SH; Jung HW; Park SH
    Neuropathology; 2007 Feb; 27(1):10-20. PubMed ID: 17319279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma.
    Kaufmann H; Krömer E; Nösslinger T; Weltermann A; Ackermann J; Reisner R; Bernhart M; Drach J
    Eur J Haematol; 2003 Sep; 71(3):179-83. PubMed ID: 12930318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.
    Chin M; Sive JI; Allen C; Roddie C; Chavda SJ; Smith D; Blombery P; Jones K; Ryland GL; Popat R; Rismani A; D'Sa S; Rabin N; Gale RE; Yong KL
    Blood Cancer J; 2017 Sep; 7(9):e610. PubMed ID: 29016571
    [No Abstract]   [Full Text] [Related]  

  • 39. Analysis of p73 and p53 gene deletions in multiple myeloma.
    Schultheis B; Krämer A; Willer A; Hegenbart U; Goldschmidt H; Hehlmann R
    Leukemia; 1999 Dec; 13(12):2099-103. PubMed ID: 10602435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.
    Herrero AB; Rojas EA; Misiewicz-Krzeminska I; Krzeminski P; Gutiérrez NC
    Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.